摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2R,3S)-nor-C-statine hydrochloride | 121506-22-7

中文名称
——
中文别名
——
英文名称
(2R,3S)-nor-C-statine hydrochloride
英文别名
(2R,3S)-3-amino-2-hydroxy-4-cyclohexylbutanoic acid hydrochloride;(2R,3S)-3-amino-4-cyclohexyl-2-hydroxybutyric acid hydrochloride;(2R, 3S)-3-amino-4-cyclohexyl-2-hydroxy butyric acid hydrochloride;(2R,3S)-3-amino-4-cyclohexyl-2-hydroxybutanoic acid;hydrochloride
(2R,3S)-nor-C-statine hydrochloride化学式
CAS
121506-22-7
化学式
C10H19NO3*ClH
mdl
——
分子量
237.727
InChiKey
NPQZMSTUVAOAFH-OULXEKPRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.15
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    83.6
  • 氢给体数:
    4
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis and structure-activity relationships of human renin inhibitors designed from angiotensinogen transition state.
    作者:Kinji IIZUKA、Tetsuhide KAMIJO、Hiromu HARADA、Kenji AKAHANE、Tetsuhiro KUBOTA、Yasuo ETOH、Iwao SHIMAOKA、Atsushi TSUBAKI、Makoto MURAKAMI、Toshiaki YAMAGUCHI、Akira IYOBE、Hideaki UMEYAMA、Yoshiaki KISO
    DOI:10.1248/cpb.38.2487
    日期:——
    The synthesis and the structure-activity relationships of renin inhibitors designed from the angiotensinogen transition state are described. These inhibitors contained residues modified at P1-P1, , P2, and P4-P3. Decrease in the size of side chain alkyl group in norstatine analog at P1 diminished the inhibitory activities of the compounds. Compound 5j, which contained valine residue instead of histidine residue at P2, inhibited potently cathepsin D (IC50=6.0×10-9 M) and pepsin (IC50=3.5×10-7 M) to the same extent as renin (IC50=8.5×10-10 M), and thus was not specific for renin. The reduction of the β-carbonyl group to methylene group in β-carbonylpropionyl residue at P4-P3 decreased the potency about 2 orders against human renin (5i : IC50=1.1×10-7 M vs. 1 : IC50=2.4 ×10-9 M). These results confirmed the rationality of our analysis of the interaction between an orally potent human renin inhibitor 1 and the active site of human renin using modeling techniques, showing that 1 fits the active site of renin favorably. The experimental details of the synthesis are presented.
    描述了基于血管紧张素原过渡态设计的肾素抑制剂的合成及其构效关系。这些抑制剂在P1-P1、P2和P4-P3位点含有修饰的残基。在P1位点,诺斯他酮类似物侧链烷基基团的尺寸减小,降低了化合物的抑制活性。化合物5j在P2位点含有缬氨酸残基而非组氨酸残基,能有效抑制猫hepsin D(IC50=6.0×10⁻⁹ M)和胃蛋白酶(IC50=3.5×10⁻⁷ M),其抑制活性与肾素相当(IC50=8.5×10⁻¹⁰ M),因此并非特异性针对肾素。P4-P3处β-羰基基团减少为亚甲基基团,使其对人肾素的效能下降了约两个数量级(5i: IC50=1.1×10⁻⁷ M vs. 1: IC50=2.4×10⁻⁹ M)。这些结果证实了我们对口服有效的人肾素抑制剂1与人肾素活性位点间相互作用的分析合理性,显示出1与肾素活性位点的适配良好。合成的实验细节也已呈现。
  • A stereoselective synthesis of the (2R, 3S)- and (2S, 3R)-3-amino-2-hydroxybutyric acid derivatives, the key components of a renin inhibitor and bestatin.
    作者:Yuko Kobayashi、Yoshiji Takemoto、Tetsuhide Kamijo、Hiromu Harada、Yoshio Ito、Shiro Terashima
    DOI:10.1016/s0040-4020(01)88510-0
    日期:1992.1
    The title synthesis was achieved by featuring the [2+2]-cycloaddition reaction of benzyloxyketene with a chiral imine derived from methyl (R)- or (S)-mandelate, alcoholysis of the formed 3,4-cis disubstituted β-lactam under acidic conditions, and reductive removal obtained by the [2+2]-cycloaddition reaction employing achiral and chiral imines derived from benzylamine, p-anisidine, di-panisylmethylamine
    通过特征在于苄氧乙烯酮与衍生自(R)-或(S)-扁桃酸甲酯的手性亚胺的[2 + 2]-环加成反应,在以下条件下醇解所形成的3,4-顺式双取代β-内酰胺,从而实现标题合成。还报道了在酸性条件下,以及使用衍生自苄胺,对苯胺,二潘尼基甲胺和(S)-1-苯基乙胺的非手性和手性亚胺通过[2 + 2]-环加成反应获得的还原性去除。[2 + 2]-环加成反应的立体选择性可以通过两性离子中间体的初步形成及其随后的旋转性闭环来解释。
  • Novel Synthesis of Three Types of C-Terminal Components of Renin Inhibitors from Unnatural (2S,3S)-Tartaric Acid.
    作者:Yuko KOBAYASHI、Teruyo MATSUMOTO、Yoshiji TAKEMOTO、Kazuhiko NAKATANI、Yoshio ITO、Tetsuhide KAMIJO、Hiromu HARADA、Shiro TERASHIMA
    DOI:10.1248/cpb.39.2550
    日期:——
    The addition reaction of cyclohexylmethylmagnesium bromide with the imine prepared from unnatural(2S, 3S)-tartaric acid was found to proceed in a highly stereoselective manner in the presence of cerium(III) chloride. A chelation-controlled mechanism could explain the stereochemical outcome of the addition reaction. The addition product could be elaborated into three types of C-terminal components of renin inhibitors by employing oxidative cleavage of the 1, 2-diol moiety, epoxide formation with inversion of configuration, and epoxide opening with a nucleophile.
    环己基甲基溴化镁与非天然(2S, 3S)-酒石酸制备的亚胺的加成反应,在氯化铈(III)存在下,表现出高度的立体选择性。螯合控制机制可以解释加成反应的立体化学结果。加成产物可以通过1, 2-二醇部分的氧化断裂、构型反转的环氧化反应和与亲核试剂的环氧化开环反应,进一步转化为三种类型的血管紧张素转化酶抑制剂的C端部分。
  • Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction
    作者:Kinji Iizuka、Tetsuhide Kamijo、Hiromu Harada、Kenji Akahane、Tetsuhiro Kubota、Hideaki Umeyama、Toshimasa Ishida、Yoshiaki Kiso
    DOI:10.1021/jm00172a005
    日期:1990.10
    (2R,3S)-3-amino-4-cyclohexyl-2-hydroxybutyric acid, named cyclohexylnorstatine (2a). The optically pure cyclohexylnorstatine was efficiently prepared from Boc-L-cyclohexylalaninol (3), and the stereochemistry of 1a was established by X-ray crystal analysis. The analyses of interaction between 1a and human renin using modeling techniques indicated that (1) the cyclohexyl group of P1 and the naphthyl
    为了合理设计有效的人肾素抑制剂,推导了人肾素复合物和血管紧张素原P1'Val的易裂位点P4 Pro的三维结构。基于这种结构,从血管紧张素原过渡态设计并合成了一种口服有效的人肾素抑制剂(1a)。抑制剂1a包含一个(2R)-3-(吗啉代羰基)-2-(1-萘基甲基)丙酰基残基(P4-P3),具有逆反酰胺键,L-组氨酸和一个新氨基酸(2R, 3S)-3-氨基-4-环己基-2-羟基丁酸,称为环己基去甲他汀(2a)。由Boc-L-环己基丙氨酸(3)有效地制备了光学纯的环己基去甲他汀,并通过X射线晶体分析确定了1a的立体化学。使用建模技术分析1a与人肾素之间的相互作用表明:(1)P1的环己基和P3的萘基分别容纳在较大的疏水性亚位点S1和S3中;(2)将P2 His的咪唑氢键合到Ser-233的侧链OH上,有助于抑制肾素。(3)将环己基去甲他汀异丙酯残基容纳在S1-S1'中。清楚地表明了立体化学在有效和特
  • A Practical Synthesis of<i>threo</i>-3-Amino-2-hydroxycarboxylic Acids
    作者:Fuyuhiko Matsuda、Teruyo Matsumoto、Masako Ohsaki、Yoshio Ito、Shiro Terashima
    DOI:10.1246/bcsj.65.360
    日期:1992.2
    An expeditious synthesis of (2R,3S)-3-amino-4-cyclohexyl-2-hydroxybutyric acid (2) and (2S,3R)-3-amino-2-hydroxy-4-phenylbutyric acid (4), the key components of the renin inhibitor (1) and bestatin (3), respectively, have been accomplished by featuring highly diastereoselective formation of cyanohydrin acetates from α-alkoxycarbonylamino aldehydes under phase-transfer conditions.
    已经通过在相转移条件下,以α-碳氧基氨基醛为起始物,进行高度非对映选择性的氰醇酸乙酯的形成,迅速合成了(2R,3S)-3-氨基-4-环己基-2-羟基丁酸(2)和(2S,3R)-3-氨基-2-羟基-4-苯基丁酸(4),这两者分别是肾素抑制剂(1)和贝斯坦(3)的关键成分。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物